Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

Several other brokerages also recently issued reports on COYA. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Performance

Coya Therapeutics stock opened at $5.84 on Tuesday. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.69. The company has a market capitalization of $97.59 million, a price-to-earnings ratio of -8.98 and a beta of 0.46. The stock has a fifty day moving average of $5.90 and a two-hundred day moving average of $6.47.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Arun Swaminathan acquired 5,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the acquisition, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have purchased 9,510 shares of company stock valued at $69,615. Insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics in the 2nd quarter valued at about $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the third quarter valued at approximately $169,000. Finally, Geode Capital Management LLC raised its holdings in Coya Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after buying an additional 4,485 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.